"Hope when daclatasvir (Daklinza) is approved here in November, many knowledgeable doctors will prescribe it 'off-label' with Sovaldi (sofosbuvir) for their patients. Gilead is so far off from completing studies of their NS5A inhibitor G..."
![]() | ||||
Remove
Are you sure you want to delete your ?
You will no longer be able to add new data to this tracker. | ||||